Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic cholestatic ... high-dose UDCA in patients with primary sclerosing cholangitis (PSC) may be harmful; adverse events, such ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

Another circumstance that calls for the use of antibiotics in the course of primary sclerosing cholangitis treatment is when ...

Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

A fundraiser has been set up for a University of South Wales graduate who’s been diagnosed with a rare and aggressive cancer ...

PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage liver disease.

Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

UK-based drugmaker Advanz Pharma has announced that following the grant of a temporary suspension, as announced on last month ...

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...